Model Development and Prospective Validation to Predict the Response to Neoadjuvant Chemotherapy in Cervical Cancer
Conditions
Cervical Cancer
Conditions: official terms
Uterine Cervical Neoplasms
Study Type
Observational
Study Phase
N/A
Study Design
Observational Model: Case-Only, Time Perspective: Prospective
Overall Status
Recruiting
Summary
Cervical cancer is one of the major health problems for chinese women. Besides surgery and radiotherapy, neoadjuvant chemotherapy has been proved to be an effective program by many studies.

However, not all patients respond well to neoadjuvant chemotherapy. Knowing the therapeutic effect of the neoadjuvant chemotherapy before receiving it can not only reduce the economic burden, but also more importantly save time to take more suitable treatments.

This study is undertaken to build a model combine both clinical and genetic factors to predict the effects of neoadjuvant chemotherapy.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 70 Years
Minimum Age: 18 Years
Gender: Female
Criteria: Inclusion Criteria:

- Untreated cervical cancer with FIGO stage Ib-IIIb

- Measurable lesions

- Possible to radical hysterectomy

- Age: 18 and older

- Karnofsky Performance Status≥ 70.

- WBC > 3,000/mm³, Hb > 9.0g/dl, Platelet > 100,000 /mm³, SGOT/SGPT < 60 IU/L, T-Bil < 1.5 mg/dL, Cr < 1.2 mg/dL, PaO2 > 80 torr, normal ECG

- Written informed consent

Exclusion Criteria:

- Previous history of cancer

- Patients with previous treatment

- Patients without information of clinical risk factors

- Patients who have active infection
Location
Tongji Hospital
Wuhan, Hubei, China
Status: Recruiting
Contact: Ma Ding, M.D. - 86-27-8362681 - dma@tjh.tjmu.edu.cn
Start Date
July 2011
Completion Date
December 2013
Sponsors
Huazhong University of Science and Technology
Source
Huazhong University of Science and Technology
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page